Clinical effect of fluticasone propionate, montelukast sodium and ketotifen in treatment of cough variant asthma in children
ZHU Xiao-Hong, TU Jin-Wei, DAI Ji-Hong
Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University/Ministry of Education Key Laboratory of Child Development and Disorders/China International Science and Technology Cooperation Base of Child Development and Critical Disorders/Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
Abstract：Objective To study the clinical effect of different combinations of fluticasone propionate (Flu), montelukast sodium (Mon) and ketotifen (Ket) in the treatment of children with cough variant asthma (CVA). Methods A total of 280 children with CVA who were admitted to the department of respiratory medicine from June 2015 to January 2018 were randomly divided into Flu+Mon+Ket, Flu+Mon, Flu+Ket, Mon+Ket, Flu, Mon and Ket groups, with 40 children in each group. The children in each group were given corresponding drug(s), and the course of treatment was 3 months for all groups. The condition of cough, cough symptom score, pulmonary function and adverse drug reactions were evaluated after 2 and 3 months of treatment. The children were followed up to observe recurrence. Results After treatment, cough symptom score tended to decrease in all 7 groups, with increases in percentage of forced expiratory volume in 1 second (FEV1%) and percentage of predicted peak expiratory flow (PEF%). After 2 months of treatment, the Flu+Mon+Ket group had a significantly lower cough symptom score and significantly higher FEV1% and PEF% than the other groups (P P P > 0.05). There was a low incidence rate of adverse events in all 7 groups, and there was no significant difference among the 7 groups (P > 0.05). The Ket group had a significantly higher recurrence rate of cough than the other groups (P P > 0.0024). Conclusions For children with CVA, a combination of Flu, Mon and Ket has a better clinical effect than a combination of two drugs and a single drug at 2 months of treatment and is safe. After 3 months of treatment, Flu or Mon alone has a similar effect to drug combination. Ket alone has a poor clinical effect and a high recurrence rate after drug withdrawal.
ZHU Xiao-Hong,TU Jin-Wei,DAI Ji-Hong. Clinical effect of fluticasone propionate, montelukast sodium and ketotifen in treatment of cough variant asthma in children[J]. CJCP, 2019, 21(4): 393-398.
Tang W, Zhou J, Miao L, et al. Clinical features in patients of cough variant asthma with normal andhigh level of exhaled fractional nitric oxide[J]. Clin Respir J, 2018, 12(2):595-600.
[2]
Saito N, Itoga M, Tamaki M, et al. Cough variant asthma patients are more depressed and anxious than classic asthma patients[J]. J Psychosom Res, 2015, 79(1):18-26.
[3]
Terasaki G, Paauw DS. Evaluation and treatment of chronic cough[J]. Med Clin North Am, 2014, 98(3):391-403.
Global Initiative for Asthma. Global strategy for asthma management and prevention (updated 2018)[EB/OL]. https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-V1.3-002.pdf.
[15]
Du W, Zhou L, Ni Y, et al. Inhaled corticosteroids improve lung function, airway hyper-responsiveness and airway inflammation but not symptom control in patients with mild intermittent asthma:a meta-analysis[J]. Exp Ther Med, 2017, 14(2):1594-1608.
[16]
Tagaya E, Kondo M, Kirishi S, et al. Effects of regular treatment with combination of salmeterol/fluticasone propionate and salmeterol alone in cough variant asthma[J]. J Asthma, 2015, 52(5):512-518.
[17]
刘传合. 正确使用哮喘治疗药物[J]. 临床药物治疗杂志, 2018, 16(6):1-3.
[18]
Morina N, Haliti A, Iljazi A, et al. Comparison of effect of leukotriene biosynthesis blockers and inhibitors of phosphodiesterase enzyme in patients with bronchial hyperreactivity[J]. Open Access Maced J Med Sci, 2018, 6(5):777-781.
Yamauchi K, Shikanai T, Nakamura Y, et al. Roles of histamine in the pathogenesis of bronchial asthma and reevaluation of the clinical usefulness of antihistamines[J]. Yakugaku Zasshi, 2011, 131(2):185-191.
